People

Dr Eli Kotler

Melbourne, Victoria, Australia

WP Kerns

Gamma hydroxybutyric acid (GHB) intoxication

P Palatini

Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers

R Padrini

Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers

GP Galloway

Abuse and therapeutic potential of gamma-hydroxybutyric acid

MA Wilson

(±3, 4-Methylenedioxymethamphetamine Selectively Damages Central Serotonergic Neurons in Nonhuman Primates

M Kaelen

The paradoxical psychological effects of lysergic acid diethylamide (LSD)

H Weinstein

Antagonism of histamine-activated adenylate cyclase in brain by D-lysergic acid diethylamide

SH Snyder

Multiple serotonin receptors: differential binding of 5-hydroxytryptamine, lysergic acid diethylamide and spiroperidol • Serotonin and lysergic acid diethylamide binding in rat brain membranes: relationship to postsynaptic serotonin receptors • Stereospecific binding ofd-lysergic acid diethylamide (LSD) to brain membranes: relationship to serotonin receptors • Binding interactions of lysergic acid diethylamide and related agents with dopamine receptors in the brain

DR Stanski

Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in man

F Vieira

Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority …

RI Memon

Effectiveness and Safety of Ketamine for Unipolar Depression: a Systematic Review

S Naveed

Effectiveness and Safety of Ketamine for Unipolar Depression: a Systematic Review

A Fida

Effectiveness and Safety of Ketamine for Unipolar Depression: a Systematic Review

GC Leal

Intravenous arketamine for treatment-resistant depression: Open-label pilot study • Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority …

ID Bandeira

Intravenous arketamine for treatment-resistant depression: Open-label pilot study

David Luke

University of Greenwich

Reid Robinson

Provo, Utah, USA

Novamind

Doug Drysdale

Boston, Massachusetts, USA

Cybin

Rakesh Jain

Austin, Texas, USA

WILD 5 Wellness

Saundra Jain

Austin, Texas, USA

WILD 5 Wellness

Blake Mycoskie

Los Angeles, California, USA

Tim Ferriss

Austin, Texas, USA

Sean Trigony

Los Angeles, California, USA

Seven Hound Ventures

Tomi Rantamäki